Research & development decreased 70.0%
Research & development changed -70.0% from the comparable as-filed period.
Ranked by interpretable importance, issuer history, magnitude, and accounting profile. No directional recommendation.
Research & development changed -70.0% from the comparable as-filed period.
Cash & equivalents changed -92.4% from the comparable as-filed period.
Working capital / assets changed -15246 basis points from the comparable as-filed period.
Shares outstanding changed +17.4% from the comparable as-filed period.
Total assets changed -38.8% from the comparable as-filed period.
Current assets changed +23.2% from the comparable as-filed period.
Current ratio changed +20.8% from the comparable as-filed period.
Stock-based compensation changed -8.7% from the comparable as-filed period.
Current liabilities changed +2.0% from the comparable as-filed period.
Working capital changed +2.2% from the comparable as-filed period.
Method Importance combines metric-family relevance, magnitude, issuer-history unusualness, persistence, and financial-statement significance. It is analytical prioritization, not a legal materiality conclusion or investment signal.